Full Breakdown
Semaglutide Use Associated with Fewer Asthma Attacks and COPD Exacerbations in Real-World Study
9/9/2026, 8:51:41 PM
Core Findings Presented at the ERS Congress
Researchers led by Professor Chloe Bloom (National Heart & Lung Institute, Imperial College London) analyzed UK electronic health records of 20,000–22,000 patients with asthma or COPD who started a GLP-1 receptor agonist versus a sulfonylurea. GLP-1 users experienced markedly fewer acute respiratory events. Semaglutide was linked to an ?40 % reduction in asthma attacks and a ?20 % reduction in COPD flare-ups compared with sulfonylurea users.
Background & Context
GLP-1 agonists are prescribed for type 2 diabetes and obesity and have shown anti-inflammatory effects in laboratory studies. This is one of the largest real-world investigations of their impact on airway disease.
Data & Statistics
- Study population: ~20,000 asthma and ~22,000 COPD patients initiating either therapy.
- Overall effect: Fewer acute respiratory attacks among GLP-1 users.
- Semaglutide-specific effect:
- Asthma: up to 40 % fewer attacks.
- COPD: up to 20 % fewer exacerbations.
- Dose relationship: Higher semaglutide doses correlated with stronger reductions.
Official Statements & Responses
Professor Bloom called the findings “encouraging” but warned they should not change prescribing practice without further evidence. She noted that patients already eligible for GLP-1 therapy may gain an additional respiratory benefit, but the drugs should not be started solely for lung disease.
Dr. Alexander Mathioudakis (ERS Group on Airway Pharmacology) highlighted the need to incorporate respiratory endpoints in future trials of metabolic therapies.
Verbatim Quotes
- “However, asthma and COPD outcomes have not been included as outcomes in GLP-1 drug trials.” — Dr. Bloom
Conflicting Reports & Gaps
The retrospective design precludes causal inference. Both experts stress that randomized trials are required to confirm benefit, assess safety, and explore outcomes beyond attack frequency.
What’s Next
Respiratory societies are urging prospective trials of GLP-1 agonists, particularly semaglutide, to evaluate lung-function trajectories, symptom burden, and quality of life. Until such data emerge, clinicians should follow existing GLP-1 prescribing guidelines.
